top of page

Therapeutic Development Pipeline

Diagnostic Pipeline

AEZS Diag_pipe_1.2023.png

Aeterna is regaining rights to macimorelin (Macrilen™) in the United States and Canada in May 2023 and is engaged in robust business development efforts to identify and secure a new development and commercialization partner in these territories. 


Specialty Biopharmaceutical Company

Data delayed 15 minutes unless otherwise indicated

bottom of page